The Food and Drug Administration considered data regarding marijuana’s medical value submitted by U.S. states with legal cannabis programs when determining how the drug should be federally classified, newly released documents suggest.
Until now, federal officials have revealed very little about the Drug Enforcement Administration’s review process in response to a Department of Health and Human Services (HHS) recommendation in August that marijuana be moved from Schedule 1 to Schedule 3 under the Controlled Substances Act.
Not even the HHS’ exact recommendations to the DEA have been disclosed.
ADVERTISEMENT
The DEA currently is considering points of law and policy in the rescheduling process that the Biden administration started in October 2022.
But a rare peek into the process surfaced last week when attorney Matt Zorn obtained and posted to Substack the heavily redacted internal documents.
The documents show that the U.S. government had “an interest in
Read full article on Marijuana Business Daily
